Eli Lilly and Company
Anti-CGRP Antibodies For Treatment-Resistant Patients

Abstract:

The invention provides for methods, treatments, and uses of anti-human calcitonin gene related peptide (CGRP) antibodies for the prevention of migraine headaches in patients that have previously failed to respond to migraine preventive medications either because of inadequate efficacy, a lack of safety, and/or tolerability.